Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: Systematic review

BMJ Oct 11, 2018

Matthews A, et al. - In women with a history of non-metastatic breast cancer, researchers examined the impact of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes. The totality of the randomized controlled trial and observational evidence suggested an increased risk of venous thromboembolism in tamoxifen users vs both non-users and aromatase inhibitor users. Data also indicated a higher risk of vascular diseases, myocardial infarction, and angina in aromatase inhibitor users vs tamoxifen users, which might be driven by a protective effect of tamoxifen.

Go to Original

Sign-up to continue reading. It is free & takes less than 2 mins

  • 45 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Free & unlimited access to original articles and quizzes
  • Nonloggedinlock icon
    Secure: we never sell your data
This article is only available to members. Are you a doctor? Click here to signup for free.
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen